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A b s t r a c t  
The aim of the present study was to develop Gastro retentive effervescent floating tablets (GREFT) 
containing 20 mg of simvastatin were developed by direct compression method using HPMC K4M, 
HPMC K15M, HPMC K100M with different drug to polymer ratio. Tablets were evaluated for their 
physical characteristics, viz., hardness, friability, drug content and floating properties. Further, 
tablets were studied for in vitro drug release characteristics for 12 h. The tablets exhibited controlled 
and prolonged drug release, with optimum hardness, consistent uniformity in weight and low 
friability. The formulation with F2 (HPMC K100M 1:3 ratio) showed 85.83 % drug release at the end 
of 12 h and exhibited optimum floating lag time. A decrease in release rate of the drug was observed 
on increasing polymer ratio and also by increasing viscosity grades of the polymer (HPMC). Drug 
release from effervescent floating matrix tablets was sustained over 12 h with buoyant properties. 
DSC study revealed that there is no drug excipient interaction. Based on the release kinetics, all 
formulations best fitted the Higuchi, first-order model and non-Fickian as the mechanism of drug 
release. Optimized formulation (F9) was selected based on the similarity factor (f2) (71.32) and 
invitro dissolution was used in radiographic studies by incorporating BaSO4. In vivo X-ray studies in 
human volunteers showed that the mean gastric residence time was 5.4 ± 0.32 h. 
Keywords: Simvastatin, Direct compression, HPMC K4M, HPMC K15M,HPMC K100M. 
 
 
 
Introduction 
Effervescent floating drug delivery systems generate gas (CO2), 
thus reduce the density of the system and remain buoyant in the 
stomach for a prolonged period of time and released the drug 
slowly at a desired rate [1]. The gastro retentive drug delivery 
systems can be retained in the stomach and assist in improving the 
oral sustained delivery of drugs that have an absorption window in 
a particular region of the gastrointestinal tract. These systems help 
in continuously releasing the drug before it reaches the absorption 
window, thus ensuring optimal bioavailability [2]. Controlled release 
(CR) dosage forms have been extensively used to improve therapy 
with several important drugs. However, the development processes 
are faced with several physiological difficulties such as the inability 
to restrain and localize the system within the desired region of the 
gastrointestinal tract and the highly variable nature of the gastric 
emptying process. This variability may lead to unpredictable 
bioavailability and time to achieve peak plasma level. On the other 
hand, incorporation of the drug in controlled release gastro 
retentive forms (CR-GRDF) which can remain in the gastric region 
for several hours would significantly prolong the gastric residence 
time of drugs and improve bioavailability, reduce drug waste, and 
enhance the solubility of drugs that are less soluble in high pH 
environment. Gastro retention would also facilitate local drug 
delivery to the stomach and proximal small intestine. Thus, gastro 
retention could help to provide greater availability of new products 
and consequently improved therapeutic activity and substantial 
benefits to patients [3]. Simvastatin is anti hyper lipidemic 
Simvastatin belong to the category of statin which inhibits the 
enzyme HMG-CoA reductase. HMG-CoA reductase catalyses the 
conversion of HMG-CoA to mevalonate, the rate limiting step in de 
novo cholesterol synthesis. Competitive inhibition of this enzyme 
by Simvastatin decreases hepatocyte cholesterol synthesis. The 
associated reduction in intracellular cholesterol concentration 
induces LDL-receptor expression on the hepatocyte cell surface. 
Which results in increased extraction of LDL-C from the blood and 
decreased circulating LDL-C concentration? Simvastatin also have 
beneficial effects on other lipid parameters including increase in 
high-density lipoprotein cholesterol (HDL-C) concentration and 
decreases in triglyceride concentration. Secondary mechanism by 
which simvastatin may reduce levels of atherogenic lipoproteins 
include inhibition of hepatic synthesis of apolipoprotein B100 and a 
reduction in the synthesis and secreation of triglyceride-rich 
lipoproteins. In addition, simvastatin may excert beneficial 
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cardiovascular effects independent of their lipid-modifying 
properties. These pleiotropic properties may be explained by 
inhibition of synthesis of nonsteroidal isoprenoid compounds, which 
are also produced from mevalonic acid and include improvement of 
endothelial cell function, modification of inflammatory responses 
and reduction of smooth muscle cell proliferation and cholesterol 
accumulation [4]. Side effects produced by the drug are abdominal 
pain, diarrhea, indigestion, and a general feeling of weakness. 
Rare side effect include joint pain, memory loss, and muscle 
cramp. Cholestatic hepatitis, hepatic cirrhosis, rhabdomyolysis and 
myosistis have been reported in patients receiving the drug 
chronically. Grapefruit juice inhibit intestinal CYP3A4 enzyme. This 
in turn slows metabolization of simvastatin and resulting in higher 
plasma levels of drug. Due to risk of toxicity patients taking 
simvastatin should avoid intake of grapefruit and grapefruit 
containing products [5]. Simvastatin has absorption window in 
upper G.I. tract, and as result display low bioavailability [6]. 
Simvastatin is difficult to formulate in to sustained release dosage 
forms because on arrival to colon (or even before) its absorption is 
diminished or nonexistent, In the present investigation efforts were 
made to increase the residence time of simvastatin at or above the 
absorption window through preparation of gastro retentive tablet 
considering the fact that it is stable under gastric condition [7].  
The purpose of this research is to prepare gastro retentive 
effervescent floating tablet consisting of polymers HPMC K4M, 
HPMC K15M, HPMC K100M and Simvastatin drug, by direct 
compression method and to evaluate their gastro-retentive and 
controlled-release properties. The effect of various formulations 
and process variables on the in- vitro floating behavior, and in- vitro 
drug release was studied. 
Materials and Methods 
Materials 
Simvastatin was a generous gift from Biocon India, Bangalore, 
India, HPMC K4M, HPMC K15M, HPMC K100M were obtained 
from Colorcon Asia Private Limited (India) and Acetonitrile (AR) 
was obtained from Merck India Ltd. Mumbai, India. All excipients 
were of USP/NF grades and all other chemicals used were of 
analytical grades. 
Method 
Preformulation studies  
The angle of repose of powder blend was determined by the funnel 
method. Both loose bulk density and tapped bulk density were 
determined. Tapping was continued until no further change in 
volume was noted. Total porosity was determined by measuring 
the volume occupied by a selected weight of a powder and the true 
volume of the powder blend. Hausner ratio indicates the flow 
properties of the granules and is measured by the ratio of tapped 
density to the bulk density. Compressibility index is an important 
measure that can be obtained from the bulk and tapped 
densities[8]. 
Fourier transform- infrared spectroscopic analysis (FT- 
IR) 
FTIR spectra of pure drug and formulation with drug were obtained 
using KBr pellet method (applying pressure of 6000 kg/cm2). 
Spectral measurements were obtained by powder diffuse 
reflectance on a FTIR spectrophotometer (Shimadzu, Model 
8400S, Japan) in the wave number region of 400-4000 cm-1 to 
study drug excipient interactions if any[9]. 
Differential scanning calorimetry (DSC) 
DSC studies (Du Pont thermal analyzer with 2010 DSC module) 
were carried out to study the thermal behaviors of pure drug and 
formulation with drug. Calorimetric measurements were made with 
the help of an empty cell (high purity alpha alumina disc) as the 
reference. The instrument was calibrated using high purity indium 
metal as standard. The DSC scans of the samples were recorded 
in nitrogen atmosphere at a heating rate of 10 °C/min [10].  
HPLC10: Chromatographic conditions 
Column : Supelcosil C18 33mmX4.6mm, 3µm or equivalent 
Detection : UV-VIS Wavelength : 238nm,Flow rate: 3.0mL/min, 
Injection volume: 5µL, Run time: 15.0 min.Filtered and degassed 
mixture of acetonitrile and dilute phosphoric acid (50:50) was 
prepared. The solution was filtered through 0.45µm membrane and 
degassed before using.5µL of standard preparation was injected in 
replicate (6 injections) and the chromatograms were recorded. 5µL 
of the test preparation was injected in duplicate and the 
chromatograms were recorded. The sensitivity of the system was 
adjusted so that the height of the principle peak in chromatogram 
obtained is at least 20% of the full scale of the recorder.  
Preparation of effervescent tablets 
Effervescent Floating tablets containing simvastatin were prepared 
by direct compression technique using varying concentrations of 
different grades of polymers with Sodium bicarbonate and citric 
acid. All the ingredients were accurately weighed and passed 
through different mesh sieves (#40) accordingly. Then, all other 
ingredients were blended uniformly in glass mortar. After sufficient 
mixing of drug as well as other components, tablets were 
compressed using rotary tablet machine (Rimek mini press -1, 10 
stations 8 mm concave punches, Karnavati Engineering Ltd, 
Mehsana, Gujarat). The weights of the tablets were kept constant 
for all formulation 
Evaluation of effervescent floating tablet formulations 
Hardness, Friability & Weight variation 
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Hardness of the tablets was tested using a Monosanto hardness 
tester. Friability of tablets was determined in Roche friabilator. Ten 
tablets were selected randomly from each batch and weighed 
individually to check for weight variation. The results are given in 
table no. 2. 
X-ray diffractometery (XRD)  
X-ray diffraction patterns of pure simvastatin and drug loaded tablet 
(F9) were recorded using (Phillips PW 1710, Tokyo, Japan) X-ray 
diffractometer with a copper target, voltage 40 Kv, current 30 MA at 
a scanning speed of 0.30 °C/min. 
In vitro buoyancy 
The in vitro buoyancy was determined by floating lag time, per the 
method described by Rosa et al, [11]. The tablets were placed in a 
100 ml beaker containing 0.1N hydrochloric acid. The time required 
for the tablet to rise to the surface of time the dosage form 
constantly remained on the surface of medium was determined as 
the total floating time.  
Drug content 
The drug content in each formulation was determined by triturating 
20 tablets and powder equivalent to average weight was added in 
100ml of 0.1N hydrochloric acid, followed by stirring for 30 minutes. 
The solution was filtered through a 0.45μ membrane filter, diluted 
suitably and the absorbance of resultant solution was measured 
HPLC. 
Determination of swelling index 
Floating matrix tablet was introduced into basket type dissolution 
apparatus containing 900mL of 0.1N HCl (pH 1.2 at 370C) at 
100rpm. The tablets were removed at definite time intervals and 
swollen weight of each tablet was determined . Swelling (%) (%) 
was calculated [12].  
Stability studies 
Stability studies were conducted for the optimized formulation F9. 
To assess their stability with respect to drug content after storing at 
40°C/75% RH for 3 months was seen. 
In vitro drug release 
The release rate of Simvastatin from floating tablets was 
determined using United States Pharmacopeia (USP) Dissolution 
Testing Apparatus 2 (paddle method; Veego Scientific, Mumbai, 
India). The dissolution test was performed using 900 ml of 0.1N 
hydrochloric acid, at 37 ± 0.5°C and 50 rpm. A sample (10 ml) of 
the solution was withdrawn from the dissolution apparatus at 
regular intervals and the samples were replaced with fresh 
dissolution medium. The samples were filtered through a 0.45μ 
membrane filter and diluted to a suitably, resultant solution was 
measured HPLC. Cumulative percentage drug release was 
calculated using an equation obtained from a standard curve. 
Drug release kinetics 
The rate and mechanism of drug release was analyzed by fitting 
the dissolution data into several mathematical models [13,14]. 
Dissolution profiles were compared with the similarity factor using 
the theoretical release profile as a reference15. Similarity factor (f2) 
is a logarithmic, reciprocal square root transformation to the sum of 
squared errors. If f2 value is between 50 and 100, the two 
dissolution profiles are considered to be similar.  
In vivo X-ray studies 
The in vivo X-ray studies were approved by the Institutional Human 
Ethical Committee of Nargund College of Pharmacy, Bangalore, 
India. The study was performed on 3 healthy male human 
volunteers, weighing between 50 and 63 kg and in an age group of 
22 ± 2 years. Before participation in these studies, a written 
consent was obtained from the volunteers and an expert radiologist 
and a physician supervised these studies. F9 was modified by 
adding 20 mg of X-ray grade barium sulfate (20 mg of lactose was 
replaced). After overnight fasting, the volunteers were fed low 
calorie food and the tablet was given to every subject with 200 mL 
water. After one hour of tablet ingestion, a glass of water was given 
to the subject. Gastric radiography was done after 1, 2, 4 and 6 h. 
The mean gastric residence time was calculated. 
Results and Discussion 
Pre formulation parameters data were presented in Table 2 and all 
the obtained values are well within the limit.  
FTIR Studies  
From the FTIR studies (Fig.1), the characteristic bands for 
important functional group of pure drug simvastatin and simvastatin 
containing formulation (F9) was identified. It was observed that  
3546 cm-1 due to Free O-H stretching, 2924 cm-1 due to 
Methylene    C-H asymmetric stretching, 1697 cm-1 due to Ester 
C=O stretching, 1268 cm-1 due to Lactone – C-O-C bend 
stretching, 1164 cm-1  due to Ester –C-O-C- bending  and  1072 
cm-1  due to secondary alcohol c-o stretching. FTIR spectra 
showed that the characteristics bands of simvastatin were not 
altered after successful encapsulation without any change in their 
position, indicating no chemical interactions between the drug and 
carriers used.  A comparison and interpretation of this region in our 
spectra agrees with their conclusions [9]. 
DSC Studies 
DSC studies were performed on pure drug and simvastatin 
containing formulation (F9) mixture exhibits a sharp endothermic 
peak at 143.74°C presented in Fig.  2. It was observed that 
presence of a endothermic peak of the drug at 143.01°C in the drug 
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simvastatin containing formulation (F9) indicates, that the drug is 
uniformly distributed in the mixture. The peak intensity 
corresponding to the melting of simvastatin decreased in the 
thermograms of simvastatin containing formulation (F9) mixture [9].  
The effervescent floating tablets of simvastatin were formulated in 
ten different batches F1 to F9 by using hydrophilic polymers HPMC 
K4M,HPMC K15M, HPMC   K100M along with effervescing agent 
sodium bicarbonate and citric acid. All the formulations were 
prepared by direct compression method. The prepared tablets of all 
the formulations were evaluated for physical characters like tablet 
hardness, friability, weight variation buoyancy lag time, total 
floating time, drug content, in-vitro drug release. The main aim was 
to optimize the formulation for 24 h in-vitro release and total 
floating time to more than 24 h. 
The measured hardness of tablets of each formulation ranged 
between 4.2 to 4.4 kg/cm2 presented in table 2.  The % friability 
was less than 1% in all the formulations ensuring that the tablets 
were mechanically stable. All the tablets passed weight variation 
test as the % weight variation was within the Pharmacopoeial limits 
of ± 5% of the weight. The content uniformity of the tablets were  
well within the Pharmacopoeial limits. 
X-ray diffraction studies 
X-ray diffraction patterns revealed the crystalline nature of pure 
simvastatin. The X-ray diffractogram of simvastatin showed 
number of sharp and intense peaks presented in Fig.3. The 
diffractogram of simvastatin loaded matrix tablet (F9) showed 
broad peaks with low intensity. This may be attributed to the 
incorporation of simvastatin between parts of the lattice of the 
HPMC K100M , leading to a change in the degree of crystallinity of 
the simvastatin. Increase in peak width was observed in XRD 
pattern of simvastatin loaded matrix tablets (F9). 
8 h, F4 BLT of 120sec and TFT of < 8h, F5 BLT of 119 sec and 
TFT of <10 h, F6 BLT of 116 sec and TFT of <10 h, F7 BLT of 114 
sec and TFT of >12 h, F8 BLT of 112 sec and TFT of >12 h, F9 
BLT of 110 sec and TFT of >12 h. Formulation F9 containing 
HPMC K100M showed good BLT of 110 sec and TFT of more than 
12 h, presented in Fig 4. In this study, penetration of water into 
tablets with high viscosity HPMC K4M was slow, causing 
increasing the gel formation and subsequent increasing  in the 
floating lag time and decreased  total floating duration (>24 hrs) 
compared to the tablets prepared with K4M and K15M. With the 
exception of formulations F1 to F4, all the formulated tablets were 
buoyant less than 8h. Different grades of HPMC (K4M, K10M & 
K100M) were used as swellable polymers. HPMC was chosen 
because it is widely used as low-density hydrocolloid system, upon 
contact with water, a hydrogel layer would be formed to act as a 
gel boundary for the delivery system [16]. Various grades of HPMC 
were reported to have a duration of buoyancy of more than 12 h in 
the simulated meal medium, as well as in distilled water [17]. Our 
focus was on the floatability of the dosage form, so the HPMC 
concentration was increased throughout the experimental design. 
As stated above, different viscosity grades of HPMC show good 
floatability 
Drug Content 
USP specifies that Simvastatin tablets contain not less than 90.0 
percent and not more than 110.0 percent of labeled amount of 
Simvastatin presented in Table 2. All the formulations complied 
with the USP specification. 
Stability studies 
Optimized formulation F9, after storing at 40±2°C /75±5% RH for 3 
months showed no changes in the drug content. 
In vitro drug release 
Formulation F1, F4, F5 & F8 showed first hour release of 
75.0478%, 80.308%, 71.420%, 77.313% respectively. These  
                                Table 1: Formulations for simvastatin floating tablets  
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 
Simvastatin 20 20 20 20 20 20 20 20 20 
HPMC K4M 40 60 80  - - - - - 
HPMC K15M - - - 40 50 60 80 - - 
HPMC K100M - - - - - - - 40 60 
Sodium bicarbonate 20 20 20 20 20 20 20 20 20 
Citric acid 5 5 5 5 5 5 5 5 5 
Dicalcium phosphate 15 15 15 15 15 15 15 15 15 
Lactose 100 80 60 100 90 80 60 100 80 
Total weight 200 200 200 200 200 200 200 200 200 
                            *All the quantities are in mg 
                       
      Table 2:  Pre formulation parameters  
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Formulatio
n 
Bulk density 
(g/cm3) 
Tap density 
(g/cm3)  % Carr’s Index Hausner’s ratio 
Angle of 
repose (θ)  
F1 0.634 0.740 14.28 1.16 
25.19 
F2 0.597 0.727 17.91 1.218 
23.89 
F3 0.625 0.727 14.06 1.163 
26.68 
F4 0.689 0.869 20.68 1.260 
26.53 
F5 0.701 0.851 17.54 1.212 
21.20 
F6 0.677 0.851 20.33 1.255 
23.77 
F7 0.714 0.833 14.28 1.166 
25.62 
F8 0.714 0.888 19.64 1.244 
24.943 
F9 0.689 0.869 20.68 1.260 
25.61 
    n=3 
 
                            Figure 1. FTIR spectra of simvastatin  and formulation F9  
        Table 3: Hardness, Friability, Weight variation of tablets of different formulation  F1 to F9 
Formulation Hardness 
(Kg/cm2) 
Friability 
(%) 
Weight 
Variation (mg) 
Drug content  
(%) 
F1 4.2 ± 0.21 0.82  204 ± 4% 
 
98.89 ± 1.4 % 
F2 4.3 ± 0.22 0.79 199 ± 3% 99.12 ± 3.2 % 
F3 4.3 ± 0.31 0.82 202 ± 4% 97.99 ± 2.4 % 
F4 4.4 ± 0.43 0.83 200 ± 5% 99.56 ± 3.5% 
F5 4.2 ± 0.31 0.86 203 ± 4% 98.99 ± 1.4 % 
F6 4.3 ± 0.33 0.76 203 ± 4% 99.32 ± 3.1% 
F7 4.2 ± 0.25 0.80 202 ± 5% 98.88 ± 2.1% 
F8 4.3 ± 0.15  0.74 202 ±  3% 99.23 ±  2.6% 
F9 4.2 ± 0.11 0.88 203 ± 4%  98.35 ±  1.4 % 
                     *Values are mean ± S.D 
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Table 4: Buoyancy Lag Time, Total Floating Time of formulations (F1toF9) 
 
Formulation 
Buoyancy 
LagTime (Sec) 
 Total Floating     
Time (h) 
Similarity factor 
      (f2) 
Swelling Index 
      (%) 
F1 128 < 8 50.14 71.32 
F2 126 < 8 56.13 97.98 
F3 124 < 8 54.98 105.23 
F4 120 <10 56.87 115.12 
F5 119 <10 53.51 123.51 
F6 116 <10 66.56 136.56 
F7 114 >12 65.33 139.33 
F8 112 >12 68.23 145.23 
F9 110 >12 71.32 156.01 
 
 
                     Figure 2. DSC thermograms of simvastatin and formulation F9  
 
     Figure 3. X-ray powder diffraction patterns of Pure simvastatin and formulation F9                     
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                                       Figure 4:  Floating behavior of Formulation F9 
 
 
 
 
Figure  5. Radiographic photo images showing the presence of a BaSO4-loaded   floating tablet  (F9) in the stomach at 
different   time periods. The tablet altered its position in the stomach. 
 
 
 
In vitro buoyancy 
Buoyancy lag time (BLT) and total floating time (TFT) of different 
formulation were noted, where F1 BLT of 128 sec and TFT of < 8 
h, F2 BLT of 126 sec and TFT of < 8h, F3 of 124 sec and TFT of < 
formulations failed to maintain integrity. As soon as the tablet gets 
disintegrated, it forms a layer of polymer on the surface. So, this 
might be the reason for the high drug release in the first h. At the 
end of 5th h, F1 formulation showed 92.31% release, F4 
formulation showed 91.81% release at the end of 6th h, F5 
formulation showed release of 96.96 % at the end of 8th h and F8 
shows 92.92 % at the end of 7th h. This sustained release of drug 
from these formulations after a high drug release in the first hour 
might be due to the slow release of drug from the polymer matrix 
which was floating as a layer [18]. 
The reason for disintegration of tablet might be due to low amount 
of polymer and high amount of water soluble diluent lactose.  
Hence the tablet was not able to withstand the pressure generated 
by the release of CO2 from the effervescent mixture. So, the 
formulations F1, F4, F5, and F8 failed as gastro-retentive dosage 
forms. Formulations F2, F3, F6, F7 & F8 showed first h release of 
6.46 %, 7.012%, 8.920%, 5.917%, 12.18% respectively and 
maintained the integrity. The F9 formulation showed 12.18 % 
release in first h. This might be due to the pores formed due to 
release of carbondioxide, and also due to erosion. The release 
may also be due to the drug which was stuck to the surface of the 
tablet.  This can be justified by swelling index and erosion index. 
The erosion index of F9 formulation at 2h is 20%.   From 2nd h to 
12th h, the release is sustained. This can be justified by swelling 
index which reaches maximum of 156% at 12th h. 
At the end of 12 h, F2 formulation showed 62.76 % drug release, F3 
formulation showed 57.835% release, F6 formulation showed 73.18 
% release, F7 formulation showed 45.653% release and F9 
formulation showed 85.76 % release. Though the F9 formulation 
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showed 12.18 % release in the 1st h, it is an advantage. Since the 
mechanism of absorption of Simvastatin is by passive diffusion, 
concentration gradient is very important. The drug release of 12.18 
% will provide the concentration gradient and it is maintained by 
the sustained release of drug. Since the formulation F9 showed the 
best release of 85.76 % at the end of 12 h, it was selected as the 
optimized formulation. Release of the drug was faster with lower 
viscosity grades of HPMC K4M due to lower gel strength, less 
entanglement and smaller diffusion path length compared to higher 
viscosity grades of HPMCs. In all the formulations, polymer 
concentration greatly affected the release of the drug. The drug 
release rate was inversely proportional to the polymer 
concentration present in the matrix. 
The first phase of the drug release profile depended on the 
concentration of the drug in the upper layer as an immediate dose 
and hence followed first-order release kinetics. In the second 
phase of the release (2-12 h), the diffusion coefficient was found to 
be 0.29 to 0.38. Based on the n value, the mechanism of 
Metaprolol Tartrate release from the floating layer followed Fickian 
transport. The optimized formulation was selected based on the 
similarity factor (f2) (14) value, The similarity factor (f2) of F9, when 
compared with the theoretical release profile, was found to be 
71.32 (Table3), which was higher than for other formulations.  
 
In vivo X-ray studies 
After ingestion of the floating tablets developed by using barium 
sulfate, the duration of the tablet in the stomach was monitored by 
radiograms presented in Fig.5. Tablet was more or less at the 
same position in stomach for the first 2 h and moved slightly 
downwards and remained within the stomach till the end of 12h. 
The change in the location of the tablet at different time points 
suggested that the tablet did not adhere to the gastric mucosa. The 
mean gastric retention time was 5.4 ± 0.32 h. 
Conclusion 
The present study was conducted to develop an effervescent 
floating drug delivery system using three grades of HPMC polymer, 
in different concentrations. Optimized formulation F9 showed an 
excellent buoyant ability and a suitable drug release pattern. This 
could be advantageous in terms of increased bioavailability of 
Metaprolol Tartrate. The developed gastroretentive drug delivery 
system provides advantages of ease of preparation and sustained 
drug release for 12 
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